UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Stock Position in Boston Scientific Corporation $BSX

Key Points

• UBS Asset Management increased its stake in Boston Scientific Corporation by 4.2%, owning approximately 11.3 million shares valued at over $1.1 billion.
• Boston Scientific reported $0.75 earnings per share in its recent quarter, exceeding analyst estimates, and experienced a 22.8% increase in revenue compared to the previous year.
• Insider sales at Boston Scientific saw executives offloading shares, with one EVP reducing their holdings by 21.90% after selling 50,000 shares at an average price of $105.43.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,299,942 shares of the medical equipment provider's stock after purchasing an additional 460,580 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.76% of Boston Scientific worth $1,139,938,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BSX. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. Invesco Ltd. increased its position in shares of Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after acquiring an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after acquiring an additional 1,383,524 shares during the last quarter. Amundi increased its position in shares of Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after acquiring an additional 311,034 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on BSX. Leerink Partners initiated coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price target for the company. Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. UBS Group raised their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Truist Financial raised their price target on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Finally, Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $118.04.

Boston Scientific Price Performance

NYSE:BSX traded down $1.63 during trading hours on Friday, hitting $102.71. 10,541,837 shares of the company's stock traded hands, compared to its average volume of 6,118,901. The firm has a market cap of $152.19 billion, a P/E ratio of 61.14, a P/E/G ratio of 2.51 and a beta of 0.65. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The business's fifty day simple moving average is $104.86 and its two-hundred day simple moving average is $102.26. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at $18,802,597.06. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 over the last three months. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.